Profile
Dr. Robert Young
Affiliation
Simon Fraser UniversityAcademy or College
Academy of ScienceYear Elected
2005Areas of Interest
Medicinal, chemistry, discovery, inflammation, asthma
LONG CITATION
Robert Young is a world leader in the chemistry and biology of prostaglandins and leukotrienes, chemical entities that play a central role in respiratory and inflammatory disease. Dr. Young has championed a strategy whereby an understanding of drug metabolism and disposition can lead to a more efficient design of drugs. At Merck Frosst, he initiated the medicinal chemistry program and did many of the early experiments that culminated in the discovery of Singulair®, a valuable medicine for the treatment of asthma. He also headed the team that discovered the drug Vioxx® and Arcoxia®, COX-2 inhibitors which have been widely prescribed for the treatment of inflammation. He has over 100 research publications and review articles, and over 50 patents.
SHORT CITATION
Robert Young is a world leader in the chemistry and biology of prostaglandins and leukotrienes, chemical entities that play a central role in respiratory and inflammatory disease. Dr. Young has championed a strategy whereby an understanding of drug metabolism and disposition can lead to a more efficient design of drugs. His work led to the discovery of effective drugs for the treatment of asthma and inflammation.